{"id":"NCT02024646","sponsor":"Bausch Health Americas, Inc.","briefTitle":"Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis","officialTitle":"A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis: AMVISION-2","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-03","primaryCompletion":"2015-10","completion":"2015-10","firstPosted":"2013-12-31","resultsPosted":"2020-08-20","lastUpdate":"2020-08-20"},"enrollment":484,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriatic Arthritis"],"interventions":[{"type":"DRUG","name":"210 mg brodalumab","otherNames":["AMG 827"]},{"type":"DRUG","name":"140 mg brodalumab","otherNames":["AMG 827"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"210 mg brodalumab","type":"EXPERIMENTAL"},{"label":"140 mg brodalumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of this study is to evaluate the efficacy of brodalumab, compared to placebo, in subjects with psoriatic arthritis. The key secondary objective is to evaluate the efficacy of brodalumab compared to placebo at week 16. The safety objective of this study is to evaluate the safety profile of brodalumab in subjects with psoriatic arthritis.","primaryOutcome":{"measure":"ACR20 (American College of Rheumatology 20% Improvement) Response Rate Through Week 16","timeFrame":"Baseline and 16 Weeks","effectByArm":[{"arm":"210 mg Brodalumab","deltaMin":41.8,"sd":null},{"arm":"140 mg Brodalumab","deltaMin":48.9,"sd":null},{"arm":"Placebo","deltaMin":24.7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":4},"locations":{"siteCount":103,"countries":["United States","Canada","France","Germany","Greece","Hungary","Latvia","Mexico","Poland","Russia"]},"refs":{"pmids":[],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":163},"commonTop":["Nasopharyngitis","Upper Respiratory Tract Infection","Diarrhoea","Nausea","Contusion"]}}